Tides Brief | Angtuo Biopharma's siRNA Drug ART101 Injection Receives IND Approval for Hypertension Treatment
Arnatar
Antisense Technology Drug Developer
About RAAS
Renin-Angiotensin-Aldosterone System (RAAS) inhibitors, commonly used in clinical practice for the treatment of hypertension, are highly effective but can cause adverse reactions such as hyperkalemia, hypotension, and acute renal failure due to the potent action of some drugs. Additionally, the short half-life of existing oral antihypertensive drugs leads to poor patient compliance, and combination therapy is sometimes required, increasing the risk of drug interactions and side effects.
About ART101 Injection
Disclosed preclinical and clinical studies show that oligonucleotide drugs targeting AGT can reduce the production of hepatic AGT by inhibiting liver AGT mRNA levels, thereby lowering systemic AGT levels and achieving the purpose of blood pressure reduction. ART101 Injection, as a siRNA drug independently developed by Arnatar, achieves a blood pressure lowering effect by targeting and inhibiting the expression of hepatic AGT mRNA, reducing the generation of AGT protein.
AboutArnatarArnatar
Arnatar Therapeutics was founded in 2022 by a global team of scientists in the field of nucleic acid drugs. The company has built a breakthrough innovative nucleic acid drug platform and continues to explore novel mechanisms of nucleic acid-based drugs, covering multiple therapeutic areas. Arnatar is leveraging its innovative antisense nucleic acid technology (Antisense Technology) and utilizing RNA interference (RNAi) and antisense oligonucleotide (ASO) platforms to modulate the expression of target genes, thereby providing opportunities for the treatment of liver, extrahepatic organ diseases, as well as common and rare diseases.